Composition for alleviating atopic skin symptoms, containing poly-gamma-glutamic acid

A technology for atopic dermatitis and glutamic acid, applied in skin care preparations, medical preparations containing active ingredients, drug combinations, etc., can solve problems such as adverse effects

Inactive Publication Date: 2019-08-30
BIOLEADERS CORP
View PDF8 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

They have excellent results, but their long-term use may have adverse effects, including excessive hair growth on treated skin, skin shrinkage, hypopigmentation, skin infections, acne, thinning of the skin so that veins are clearly visible

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for alleviating atopic skin symptoms, containing poly-gamma-glutamic acid
  • Composition for alleviating atopic skin symptoms, containing poly-gamma-glutamic acid
  • Composition for alleviating atopic skin symptoms, containing poly-gamma-glutamic acid

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1 to Embodiment 3 and comparative example 1 and comparative example 2

[0028] In the content ratio specified in Table 1 below, high-molecular-weight poly-γ-glutamic acid (2,000 kDa; hereinafter referred to as "HM-PGA") and low molecular weight poly-γ-glutamic acid (1kDa; hereinafter referred to as "LM-PGA"), to prepare 2 cream formulations.

[0029] Table 1

[0030]

experiment example 1

[0031] Experimental Example 1: Evaluation of the effect of formulations containing HM-PGA alone or LM-PGA alone or a combination of the two in improving symptoms of atopic dermatitis

[0032] Each of the formulations of Examples 1 to 3 and Comparative Examples 1 and 2 were administered to 10 participants (male or female, different ages) suffering from symptoms of atopic dermatitis for 1 week. Each participant was asked to self-assess the intensity and frequency of itching before and after application of the formulation and the intensity of itching during sleep. The evaluation results are shown in Table 2 below (unit: person).

[0033] -Test object

[0034] (1) Gender: male (50%), female (50%)

[0035] (2) Age: 5 to 9 years old (50%), 10 to 15 years old (33%), 15 to 19 years old (17%)

[0036]

[0037] As can be seen from Table 2, the formulations of Comparative Example 1 and Comparative Example 2, which used one of the two active ingredients of the present invention alon...

experiment example 2

[0039] Experimental Example 2: Skin Patch Stability Test

[0040] The formulations of Examples 1 to 3 were evaluated for stability as skin patches.

[0041] A skin patch trial was completed on 33 participants using the Finn Chamber. The back of each participant was washed with 70% ethanol and dried, and 20 μl of the test substance was added dropwise on an 8 mm diameter Finn Chamber. The patch is placed on the back and removed after 24 hours. Skin reactions were read at 30 minutes, 24 hours and 48 hours after application. The procedures were performed by dermatologists, and the assessment was performed according to the criteria of the International Contact Dermatitis Research Group (ICDRG). The evaluation results are shown in Table 3 below.

[0042] table 3

[0043]

[0044] As can be seen in Table 3, the composition of the present invention elicited a skin reaction of 0.00 at 30 minutes, 24 hours and 48 hours after removal of the patch and was considered "non-irritatin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a composition for alleviating atopic skin symptoms, containing, as active ingredients, high molecular weight poly-gamma-glutamic acid and low molecular weight poly-gamma-glutamic acid. The composition according to the present invention inhibits epidermal and transdermal moisture loss, removes keratinous materials, provides excellent skin soothing properties, and alleviates itching caused by drying, thereby providing a superior alleviation effect throughout atopic skin symptoms.

Description

technical field [0001] The present invention relates to a composition comprising poly-gamma-glutamic acid for alleviating the symptoms of atopic dermatitis, more particularly, to a composition comprising high-molecular-weight poly-gamma-glutamic acid and low-molecular-weight poly-gamma-glutamic acid as active A composition of ingredients to provide an effective means of improving the symptoms of atopic dermatitis. Background technique [0002] Atopic dermatitis is a skin disease that usually occurs in 0.5% to 1% of the world's population. It affects 5% to 10% of children and usually occurs between 2 and 6 months of age. Most cases of atopic dermatitis appear in the first year of life, and 85% appear in children under 5 years of age. Fifty percent of people who develop atopy in childhood go into remission within the first two years of life. Twenty-five percent of children with atopic dermatitis also have the condition during adolescence, and the remaining 25 percent contin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/765A61K8/88A61Q19/00
CPCA61K8/88A61K31/765A61Q19/00A61K31/785A61P17/00A61P29/00A61K9/0014
Inventor 崔在喆李日汉赵希晋金升勋
Owner BIOLEADERS CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap